

Mariateresa Fulciniti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11756105/publications.pdf>

Version: 2024-02-01

21
papers

3,867
citations

471371

17
h-index

752573

20
g-index

22
all docs

22
docs citations

22
times ranked

8380
citing authors

#	ARTICLE	IF	CITATIONS
1	Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. <i>Nature Communications</i> , 2014, 5, 2997.	5.8	741
2	Blockade of XBP1 splicing by inhibition of IRE1 α is a promising therapeutic option in multiple myeloma. <i>Blood</i> , 2012, 119, 5772-5781.	0.6	353
3	Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. <i>Blood</i> , 2018, 132, 587-597.	0.6	335
4	A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. <i>Leukemia</i> , 2019, 33, 159-170.	3.3	313
5	Elevated IL-17 produced by Th17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. <i>Blood</i> , 2010, 115, 5385-5392.	0.6	300
6	Targeted Disruption of the BCL9/ β -Catenin Complex Inhibits Oncogenic Wnt Signaling. <i>Science Translational Medicine</i> , 2012, 4, 148ra117.	5.8	214
7	Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. <i>Journal of Clinical Investigation</i> , 2008, 118, 491-504.	3.9	202
8	The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells <i>In vitro</i> and <i>In vivo</i> . <i>Clinical Cancer Research</i> , 2009, 15, 4028-4037.	3.2	200
9	Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 5124-5129.	3.3	196
10	Genomic landscape and chronological reconstruction of driver events in multiple myeloma. <i>Nature Communications</i> , 2019, 10, 3835.	5.8	183
11	Drugging the lncRNA MALAT1 via LNA gapmer ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. <i>Leukemia</i> , 2018, 32, 1948-1957.	3.3	179
12	PI3K/p110 α is a novel therapeutic target in multiple myeloma. <i>Blood</i> , 2010, 116, 1460-1468.	0.6	177
13	Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. <i>Blood</i> , 2012, 120, 1877-1887.	0.6	162
14	Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1364-1375.	1.9	94
15	The Cyclophilin A α -CD147 complex promotes the proliferation and homing of multiple myeloma cells. <i>Nature Medicine</i> , 2015, 21, 572-580.	15.2	79
16	Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1364-1375.	1.9	60
17	Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. <i>Journal of Clinical Oncology</i> , 2020, 38, 3107-3118.	0.8	45
18	CRISPR Interference (CRISPRi) and CRISPR Activation (CRISPRa) to Explore the Oncogenic lncRNA Network. <i>Methods in Molecular Biology</i> , 2021, 2348, 189-204.	0.4	12

#	ARTICLE	IF	CITATIONS
19	The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma. <i>Leukemia</i> , 2020, 34, 167-179.	3.3	11
20	Deficiency of IL-17A, but not the prototypical Th17 transcription factor ROR γ t, decreases murine spontaneous intestinal tumorigenesis. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 13-24.	2.0	10
21	Role of Wnt Signaling Pathways in Multiple Myeloma Pathogenesis. , 2013, , 85-95.		1